ModerateSelective serotonin reuptake inhibitors (SSRIs)×Synthetic steroid with estrogenic, progestogenic and weak androgenic activity
Updated · Methodology
Mechanism
In laboratory studies, tibolone had minimal effects on cytochrome P450 enzymes, but in people it moderately changed the pharmacokinetics of midazolam, a substance metabolised by the CYP3A4 enzyme. Interactions of tibolone with other CYP3A4 substrates therefore cannot be ruled out (Boltin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Sertraline is metabolised by several pathways, including CYP3A4, CYP2C19 and CYP2B6, and its levels depend on CYP3A4 activity. Grapefruit juice raised them by about 100%, and even larger increases with strong CYP3A4 inhibitors cannot be ruled out (Besitran SmPC, AEMPS). The documents do not describe tibolone as an inhibitor or inducer of CYP3A4 and do not say how much or in which direction it could change sertraline levels. There is no effect the other way round: sertraline does not inhibit CYP3A4 to a clinically significant degree, and drugs metabolised by CYP3A4 need no dose adjustment with it (Besitran SmPC, AEMPS; Zoloft label, US Food and Drug Administration, FDA).
Symptoms
The documents describe no symptoms linked to this combination. Selective serotonin reuptake inhibitors (SSRIs), including sertraline, can cause abnormal bleeding, including gastrointestinal and gynaecological haemorrhage (Besitran SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Tibolone often causes vaginal bleeding and spotting in the first months of treatment (Boltin SmPC, AEMPS). The most common adverse effects of sertraline are nausea, diarrhoea, dry mouth, insomnia, dizziness, headache, drowsiness and fatigue (Besitran SmPC, AEMPS).
Management
No document contraindicates this combination or calls for a dose change because of it (Boltin and Besitran SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS; Zoloft label, US Food and Drug Administration, FDA). According to the tibolone SmPC, interactions with substances metabolised by the CYP3A4 enzyme cannot be ruled out, and sertraline is partly metabolised by this enzyme, but the SmPC gives no action for this situation (Boltin and Besitran SmPCs, AEMPS). Sertraline is used with caution in people with a history of bleeding disorders and in those taking drugs that affect platelet function, such as anticoagulants, acetylsalicylic acid and non-steroidal anti-inflammatory drugs (Besitran SmPC, AEMPS). Tibolone is not among these examples. Tibolone is started only when menopausal symptoms adversely affect quality of life, and benefits and risks are reassessed at least once a year (Boltin SmPC, AEMPS). Bleeding and spotting are common in the first months of tibolone. If they continue after 6 months, start later or persist after stopping treatment, a gynaecological examination is carried out, which may include an endometrial biopsy, to exclude cancer (Boltin SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Sertralina (Besitran 50 mg) (nº registro 59717), secciones 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 59717, revisión 08/2025, secciones 4.4 y 4.5
- FDA: Zoloft (sertraline hydrochloride) prescribing information (2023)– FDA label, Viatris Specialty LLC, DailyMed setid fda754f6-d0f3-4dce-a17a-927d64f912f7, revised 08/2023, sections 4, 5.2 and 7.1
- AEMPS: Ficha técnica: Tibolona, Boltin 2,5 mg (nº registro 60100), sección 4.5 (2021)– AEMPS, CIMA, nº registro 60100 (Boltin 2,5 mg comprimidos, Organon Salud), revisión 03/2021 (texto revisado 08/2020), secciones 4.4, 4.5 y 4.8